AzTrials
AzTrials

Symptomatic Irreversible PulpitisPhase 3NCT07146997

Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness

A Phase 3 study testing Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB, Group III - Serratiopeptidase Group and Group IV - Combination Group (Ibuprofen and Serratiopeptidase) in people with Symptomatic Irreversible Pulpitis, run by Zahoor khan at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This clinical study investigates whether the combination of ibuprofen and serratiopeptidase as oral premedication can enhance the effectiveness of the inferior alveolar nerve block (IANB) in patients with symptomatic irreversible pulpitis in mandibular teeth. Read more about this study

Who is it for?
Ages 18 to 45 years
Conditions the study is for
Symptomatic Irreversible Pulpitis
What is being tested?
Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB, Group III - Serratiopeptidase Group and Group IV - Combination Group (Ibuprofen and Serratiopeptidase)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
96 participants
Where
1 sitePakistan
Study dates
23 Nov 2023to 23 Nov 2024
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age group of subjects between 18-45 years
  • Normal PDL appearance on IOPA
  • No analgesics taken 12 hours prior to study
  • Mandibular molars and premolars with deep carious lesion having sign and symptom of symptomatic irreversible pulpitis

Who cannot join

  • Presence of periapical radiolucency on IOPA
  • Teeth tender to percussion /traumatic teeth
  • Allergy to medications/anesthetic solution
  • Pregnant patient \& systemic illness
  • Patient in which local anesthesia is not effective in first attempt
  • Patient not giving consent

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • HITEC-IMS Taxila

    Rawalpindi, Punjab Province, 47080

Other trials in Pakistan

About this study

Official title: Evaluation of Combined Effect of Oral Premedications on Enhancing the Effectiveness of Inferior Alveolar Nerve Block in Mandibular Teeth With Symptomatic Irreversible Pulpitis

This clinical study investigates whether the combination of ibuprofen and serratiopeptidase as oral premedication can enhance the effectiveness of the inferior alveolar nerve block (IANB) in patients with symptomatic irreversible pulpitis in mandibular teeth. Due to the inflammatory nature of the condition, standard IANB often fails, possibly due to prostaglandin-induced nerve sensitization.

A total of 96 patients meeting specific inclusion criteria will be divided into four groups:

Read more

Placebo

Ibuprofen alone

Serratiopeptidase alone

Combination of ibuprofen and serratiopeptidase

Pain levels will be measured using the Verbal Numerical Scale (VNS) at various treatment stages. The success of anesthesia will be determined by the absence or presence of pain during access cavity preparation and initial root canal instrumentation. Statistical analysis will compare the effectiveness between groups, with the goal of determining whether combined premedication significantly improves IANB success.

The study is conducted at the Department of Operative Dentistry \& Endodontics, HITEC-IMS Taxila, over a period of six months.

Read the detailed description

Detailed Description of the Study Title Evaluation of Combined Effect of Oral Premedication on Enhancing the Effectiveness of Inferior Alveolar Nerve Block in Mandibular Teeth with Symptomatic Irreversible Pulpitis

Background and Rationale Achieving effective local anesthesia is a cornerstone of pain-free endodontic treatment. The inferior alveolar nerve block (IANB) is commonly used to anesthetize mandibular teeth. However, its success rate significantly drops in cases of symptomatic irreversible pulpitis, primarily due to inflammatory changes, nerve sensitization, and increased prostaglandin production. Prostaglandins, synthesized via the cyclooxygenase (COX-1 and COX-2) pathway, lower the pain threshold and reduce anesthetic efficacy.

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are widely used to reduce inflammation by inhibiting COX enzymes, thereby decreasing prostaglandin production. Several studies have shown that preoperative ibuprofen can enhance the effectiveness of IANB. However, other studies report conflicting results.

On the other hand, serratiopeptidase is a proteolytic enzyme known for its anti-inflammatory, mucolytic, fibrinolytic, and analgesic properties. It also acts on the COX pathway and reduces prostaglandin levels, offering a potentially synergistic effect with NSAIDs.

This study aims to evaluate the combined effect of ibuprofen and serratiopeptidase as premedication on improving the effectiveness of IANB in mandibular teeth with symptomatic irreversible pulpitis. To date, no published research has explored the combined preoperative use of these two agents for this purpose.

Objective To evaluate whether combined oral premedication with ibuprofen and serratiopeptidase enhances the anesthetic effectiveness of inferior alveolar nerve block in mandibular teeth diagnosed with symptomatic irreversible pulpitis, compared to individual or no premedication.

Research Question Does the combined oral premedication of ibuprofen and serratiopeptidase improve the success rate of IANB more than when either drug is used alone or a placebo is given?

Hypothesis Null Hypothesis (H₀): Combined oral premedication with ibuprofen and serratiopeptidase has no significant effect on the effectiveness of IANB.

Alternative Hypothesis (H₁): Combined oral premedication with ibuprofen and serratiopeptidase enhances the effectiveness of IANB.

Study Design A prospective, randomized, controlled clinical trial using non-probability consecutive sampling.

Study Setting and Duration Conducted in the Department of Operative Dentistry \& Endodontics, Dental College HITEC-IMS, Taxila, over a period of 6 months following ethical and institutional approval.

Sample Size A total of 96 patients will be enrolled (24 patients per group), calculated using 80% study power, a 5% level of significance, and expected success rates of ibuprofen (78%) and serratiopeptidase (76.3%).

Eligibility Criteria

Inclusion Criteria:

Age between 18-45 years

Mandibular molars or premolars with deep carious lesions

Clinical diagnosis of symptomatic irreversible pulpitis

Normal periodontal ligament (PDL) space on IOPA

No analgesics taken within 12 hours of treatment

Exclusion Criteria:

Presence of periapical radiolucency

Teeth tender to percussion

Allergy to any of the drugs or anesthetic solution

Pregnancy or systemic illness

Failure of local anesthesia on first attempt

Patients not providing informed consent

Group Allocation

Patients will be randomly assigned to one of four groups:

Group Premedication Dosage (to be specified) I Placebo - II Ibuprofen [Standard dose] III Serratiopeptidase [Standard dose] IV Ibuprofen + Serratiopeptidase [Standard dose each]

Methodology

After obtaining informed consent, patients will receive their assigned premedication orally one hour prior to anesthesia. Pain levels will be assessed using the Verbal Numerical Scale (VNS) at the following stages:

Before premedication

After IANB administration

During access cavity preparation

At first file placement in the canal

The IANB will be performed using 2% lidocaine with 1:100,000 epinephrine (MEDICAINE - Korea). Lip numbness will confirm successful anesthesia. If lip numbness is absent, supplemental anesthesia will be administered. Only those achieving effective block (confirmed lip numbness) will proceed to treatment.

Pain perception will be categorized:

0-3: No or mild pain (Success)

4-10: Moderate to severe pain (Failure)

Rubber dam isolation and root canal procedures will be done by a single operator to ensure consistency. Data will be recorded in a coded proforma (Annexure B).

Data Collection Tools Patient data will be collected using a structured proforma (Annexure B).

Consent forms will be signed in both English and Urdu (Annexure A).

Data Analysis

Data will be analyzed using SPSS version 26:

Quantitative variables (age, weight): Mean ± Standard Deviation

Qualitative variables (gender, group success rates): Frequencies and Percentages

Statistical Tests:

Chi-square test for qualitative comparisons

Post hoc Bonferroni test for intergroup pain score comparisons

P-value ≤ 0.05 will be considered statistically significant

Ethical Considerations Approval will be obtained from the CPSP registration and research cell and the Institutional Review and Ethical Board.

All participants will be informed in detail and will sign a bilingual consent form.

Confidentiality of patient data will be strictly maintained.

Participation is voluntary, and patients may withdraw at any time.

Expected Outcome It is anticipated that patients receiving combined ibuprofen and serratiopeptidase premedication will show a higher success rate of IANB compared to those receiving either drug alone or placebo. If confirmed, this approach could improve anesthetic protocols in endodontic treatment of inflamed mandibular teeth.

Being tested
Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB, Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB, Group III - Serratiopeptidase Group, Group IV - Combination Group (Ibuprofen and Serratiopeptidase)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANBDietary supplement

    Group I - Placebo Group (Control) Intervention: Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB.

    Purpose: This group serves as the control to establish a baseline anesthetic success rate without active premedication.

    Expected Outcome: Lower IANB success rate due to lack of anti-inflammatory intervention.

  • Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANBDrug

    Group II - Ibuprofen Group Intervention: Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB.

    Purpose: Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and inflammation, which can enhance anesthetic efficacy.

    Expected Outcome: Improved IANB success rate compared to placebo, but possibly lower than combination therapy.

  • Group III - Serratiopeptidase GroupDrug

    Group III - Serratiopeptidase Group Intervention: Patients will receive serratiopeptidase (10 mg or standard dose) orally, 1 hour before the IANB.

    Purpose: Serratiopeptidase is a proteolytic enzyme with anti-inflammatory, mucolytic, and fibrinolytic properties. It helps reduce tissue inflammation by breaking down inflammatory mediators and possibly inhibiting prostaglandin production.

    Expected Outcome: Improved IANB success rate compared to placebo; effectiveness may vary compared to ibuprofen alone

  • Group IV - Combination Group (Ibuprofen and Serratiopeptidase)Combination product

    Group IV - Combination Group (Ibuprofen and Serratiopeptidase) Intervention: Patients will receive a combination of ibuprofen and serratiopeptidase orally, 1 hour before IANB. The doses will be the same as those used in Groups II and III, respectively.

    Purpose: This group is designed to test the synergistic effect of combining an NSAID (ibuprofen) and a proteolytic enzyme (serratiopeptidase) to maximize inflammation control and increase the success of IANB in inflamed pulp tissue.

    Expected Outcome: Highest success rate of IANB due to dual action on prostaglandin inhibition and tissue inflammation reduction

Study groups in NCT07146997
Study groupRoleWhat they receive
Group I - Placebo Group (Control)Placebo comparatorGroup I - Placebo: Participants will receive an oral placebo capsule identical in appearance to the active medications, administered one hour before IANB, to serve as the control group for comparison of anesthetic effectiveness
Receives: Dietary Supplement: Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB
Group II - Ibuprofen GroupActive comparatorGroup II - Ibuprofen: Participants will receive a single oral dose of ibuprofen (400 mg) administered one hour prior to IANB to evaluate its effect on improving anesthetic success in symptomatic irreversible pulpitis
Receives: Drug: Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB
Group III - Serratiopeptidase GroupActive comparatorGroup III - Serratiopeptidase: Participants will receive a single oral dose of serratiopeptidase (10 mg) one hour before IANB to assess its effect on enhancing anesthetic efficacy in symptomatic irreversible pulpitis
Receives: Drug: Group III - Serratiopeptidase Group
Group IV - Combination Group (Ibuprofen and Serratiopeptidase)Active comparatorGroup IV - Combination (Ibuprofen and Serratiopeptidase): Participants will receive a single oral dose of ibuprofen (400 mg) and serratiopeptidase (10 mg) one hour before IANB to assess the combined effect on enhancing anesthetic success in symptomatic irreversible pulpitis
Receives: Combination Product: Group IV - Combination Group (Ibuprofen and Serratiopeptidase)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effectiveness of Inferior Alveolar Nerve Block (IANB

    Effectiveness of Inferior Alveolar Nerve Block (IANB)

    Measured by the success rate of IANB in mandibular teeth with symptomatic irreversible pulpitis.

    Success is defined as:

    No pain or mild pain (VNS score 0-3) during:

    Access cavity preparation

    First file placement in the root canal

    Failure is defined as:

    Moderate to severe pain (VNS score 4-10) during the same stages.

    This will be compared among the four study groups (Placebo, Ibuprofen, Serratiopeptidase, and Combination therapy).

    Measured: Time Frame: Perioperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2025
  2. Study start23 Nov 2023
  3. Primary completion23 Nov 2024
  4. Study completion23 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
96 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07146997
Sponsor's protocol ID
Dental/HITEC/IRB/60
Status last verified
Nov 2023
First submitted
13 Aug 2025
Last updated
9 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB, Group III - Serratiopeptidase Group and Group IV - Combination Group (Ibuprofen and Serratiopeptidase) in people with Symptomatic Irreversible Pulpitis, run by Zahoor khan at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effectiveness of Inferior Alveolar Nerve Block (IANB (time frame: Time Frame: Perioperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in